1 Recruiting To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
  • Clostridium Difficile Infection
  • Drug: ridinilazole
  • Drug: vancomycin
  • Physicians Research Group
    Tempe, Arizona, United States
  • Rajiv Parikh MD
    Tempe, Arizona, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas, United States
  • (and 105 more…)
2 Recruiting Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
  • HIV-1-infection
  • Drug: Oral Lenacapavir
  • Drug: Placebo oral tablet
  • Drug: Subcutaneous Lenacapavir
  • (and 2 more…)
  • Ruane Clinical Research Group Inc
    Los Angeles, California, United States
  • Mills Clinical Research
    Los Angeles, California, United States
  • Eisenhower Health Center at Rimrock
    Palm Springs, California, United States
  • (and 30 more…)
3 Recruiting Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV
  • HIV-1-infection
  • Drug: Oral Lenacapavir
  • Drug: F/TAF
  • Drug: Subcutaneous Lenacapavir
  • (and 3 more…)
  • Alabama Medical Group, PC (Drug Shipment Address)
    Mobile, Alabama, United States
  • Valleywise Community Health Center – McDowell
    Phoenix, Arizona, United States
  • Pueblo Family Physicians
    Phoenix, Arizona, United States
  • (and 54 more…)
4 Recruiting Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters
  • HIV-1-infection
  • Drug: B/F/TAF
  • Miller Children’s & Women’s Hospital Long Beach
    Long Beach, California, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida, United States
  • University of South Florida
    Tampa, Florida, United States
  • (and 8 more…)
5 Recruiting Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
  • HIV-1/HBV Co-Infection
  • Drug: B/F/TAF
  • Drug: Placebo to match DTG
  • Drug: Placebo to match F/TDF
  • (and 3 more…)
  • Spectrum Medical Group
    Phoenix, Arizona, United States
  • University of California Davis, One Community Health
    Sacramento, California, United States
  • Yale University; School of Medicine
    New Haven, Connecticut, United States
  • (and 83 more…)
6 Recruiting Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
  • HIV-1 Infection
  • Drug: DOR/ISL
  • Drug: BIC/FTC/TAF
  • Drug: Placebo to BIC/FTC/TAF
  • Drug: Placebo to DOR/ISL
  • University of Alabama at Birmingham 1917 Research Clinic ( Site 5610)
    Birmingham, Alabama, United States
  • Pueblo Family Physicians ( Site 5606)
    Phoenix, Arizona, United States
  • Ruane Clinical Research Group, Inc. ( Site 5624)
    Los Angeles, California, United States
  • (and 21 more…)
7 Recruiting Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017))
  • HIV Infection
  • Drug: DOR/ISL
  • Georgetown University Hospital ( Site 1018)
    Washington, District of Columbia, United States
  • Midway Immunology and Research ( Site 1030)
    Fort Pierce, Florida, United States
  • Orlando Immunology Center ( Site 1007)
    Orlando, Florida, United States
  • (and 43 more…)
8 Recruiting Expanded Access Treatment Protocol: Remdesivir for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) (GS-US-540-5821)
  • COVID-19

 

  • Drug: Remdesivir
  • Major Inclusion/Exclusion Criteria:

    1. Hospitalized with confirmed positive COVID-19 test
    2. 18 years or older
    3. On ventilator or tracheostomy
9 Not yet Recruiting Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With CoronaVirus Induced Disease 2019 (COVID-19) and Pulmonary Distress   

  • COVID-19

 

  • Drug: Ibrutinib
  • Major Inclusion/Exclusion Criteria: 
  1. Hospitalized with confirmed positive COVID-19 test
  2. 18 years or older
  3. On ventilator
  4. Uncontrolled High Blood Pressure